Lilly manufacturing reinspections
Executive Summary
FDA has begun reinspecting Lilly's manufacturing facilities for the antidepressant Cymbalta and intramuscular antipsychotic Zyprexa IM. "The reinspections began in early May 2003," Lilly says in its 10-Q filed with the Securities & Exchange Commission May 8. FDA arrived in Indianapolis May 5. The company told investors April 22 that Cymbalta's (duloxetine) fill-finish facility was ready for reinspection, while Zyprexa IM (olanzapine) would be ready for reinspection later this year (1"The Pink Sheet" April 28, p. 31)...
You may also be interested in...
Lilly GMPs Will Not Deter Product Rollout, Firm Says
The remaining Lilly products delayed by good manufacturing practices compliance problems could be approved by FDA before the company has fully implemented its GMP improvement program
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.